Vidac Pharma Announces Completion of Patient Enrollment in Phase 2B Study of VDA-1102 for High-Risk Actinic Keratosis
All 39 patients enrolled; follow-up continues as planned vidac Pharma Holdings Plc (Xetr:XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) LONDON, UNITED KINGDOM, June 15, 2026 /EINPresswire.com/ -- Vidac Pharma Holdings Plc. announces the …